Pretty amazing that it has come to this. Here is a drug that ostensibly produces less than 0.9% of normal dystrophin, in a manner that is statistically significant only if you set some of the baseline values at 0 rather than the lower limit of detection.
The fact that we're even discussing these data as part of the basis for approval is a testament to the lobbying efforts of the families.
With this upcoming analysis, I think they're supposed to be analyzing before and after samples from the same participant. If they do a paired analysis, minuscule "increases" in dystrophin are likely to be stat sig.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.